Cite
HARVARD Citation
De Velasco Oria, G. et al. (n.d.). 173P First-in-human study to evaluate the safety and clinical activity of FS222: A tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors. Immuno-oncology technology. p. . [Online].